SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
SELLAS Life Sciences Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$10.49+0.51 (+5.11%)
Close on Oct 19, 2026
- Market cap
- $1.98B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$8.35 (+390.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.98B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 14.42
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$32.46M
- EPS, diluted
- -$0.21
- Book value per share
- $0.73
- Diluted shares
- 189M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$35.22M
Net income
-$32.46M
EPS, diluted
-$0.21
Free cash flow
–
Reported periodTrailing twelve months